论文部分内容阅读
目的研究血管内皮生长因子(VEGF)与多发性骨髓瘤(MM)的关系,探索其临床意义。方法用双抗体夹心酶联免疫吸附测定法,检测37例MM患者不同时期的VEGF血清浓度,观察其与MM临床分期、肿瘤量分级、治疗效果和骨损评分的关系。结果MM患者血清中的VEGF较正常人明显升高;MM患者Ⅰ期、Ⅱ期的VEGF血清水平显著低于Ⅲ期,而Ⅰ、Ⅱ期之间差异无统计学意义;不同肿瘤量分级的MM患者间血清总VEGF含量差异有显著性;MM治疗有效者,血清VEGF水平比治疗前明显降低,而治疗无效者,其血清VEGF水平与治疗前比较差异无统计学意义;不同骨损评分组间VEGF含量差异无统计学意义。结论血管生成调控因子VEGF血清水平与MM的疾病严重程度有关。
Objective To study the relationship between vascular endothelial growth factor (VEGF) and multiple myeloma (MM) and explore its clinical significance. Methods The serum levels of VEGF in 37 patients with MM were measured by double antibody sandwich enzyme-linked immunosorbent assay (ELISA), and their relationship with clinical stage, tumor grade, therapeutic effect and bone loss score were observed. Results The serum levels of VEGF in MM patients were significantly higher than those in normal controls. The serum levels of VEGF in stage Ⅰ and stage Ⅱ of MM patients were significantly lower than those in stage Ⅲ, but there was no significant difference between stage Ⅰ and stage Ⅱ. There was significant difference in the total serum VEGF levels between the two groups. In the MM-treated group, the level of serum VEGF was significantly lower than that before treatment, while the level of serum VEGF was not significantly different between the two groups There was no significant difference in VEGF content. Conclusions The serum level of angiogenic regulatory factor VEGF is related to the severity of MM.